Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis
01 Pubblicazione su rivista
Deneau Mark R, Mack Cara, Abdou Reham, Amin Mansi, Amir Achiya, Auth Marcus, Bazerbachi Fateh, Marie Broderick Anne, Chan Albert, Diguglielmo Matthew, El-Matary Wael, El-Youssef Mounif, Ferrari Federica, Furuya Katryn N, Gottrand Frederic, Gupta Nitika, Homan Matjaž, Jensen M K, Kamath Binita M, Mo Kim Kyung, Kolho Kaija-Leena, Konidari Anastasia, Koot Bart, Iorio Raffaele, Martinez Mercedes, Mohan Parvathi, Palle Sirish, Papadopoulou Alexandra, Ricciuto Amanda, Saubermann Lawrence, Sathya Pushpa, Shteyer Eyal, Smolka Vratislav, Tanaka Atsushi, Valentino Pamela L, Varier Raghu, Venkat Veena, Vitola Bernadette, Vos Miriam B, Woynarowski Marek, Yap Jason, Miloh Tamir
DOI: 10.1002/hep4.1251
ISSN: 2471-254X
Adverse clinical events in primary sclerosing cholangitis (PSC) happen too slowly to capture during clinical trials. Surrogate endpoints are needed, but no such validated endpoints exist for children with PSC. We evaluated the association between gamma glutamyltransferase (GGT) reduction and long-term outcomes in pediatric PSC patients. We evaluated GGT normalization ( 75% versus 75% by 1 year after PSC diagnosis predicts favorable 5-year outcomes in children. GGT has promise as a potential surrogate endpoint in future clinical trials for pediatric PSC.